Valneva's Stock Poised for Potential Revaluation Amid Key Upcoming Events

Valneva's 2026 outlook hinges on Lyme vaccine VLA15 data and strategic investor moves. Revenue is expected to dip as the company transitions to its core vaccine portfolio.

Two significant developments expected in the coming weeks could fundamentally alter the investment thesis for French vaccine specialist Valneva. While the release of full-year 2025 results on March 18th provides one catalyst, the greater focus lies elsewhere.

Shareholder Base Sees Strategic Realignment

Ahead of these pivotal events, a notable shift has occurred among the company's major state-backed investors. Bpifrance elected to reduce its stake, while Caisse des Dépôts increased its shareholding through additional purchases. This internal reallocation maintains the overall level of state influence but changes its composition.

Financial Snapshot: Solid Cash, Transitional Revenue

Valneva has already communicated the key financial figures for 2025. Total revenue saw a modest increase to €174.7 million, primarily supported by its established travel vaccine portfolio. The firm ended the year with a cash position of €109.7 million—a solid, though not extravagant, reserve for a company in late-stage clinical development.

Management guidance for 2026 anticipates revenue declining to a range of €155 to €170 million. This expected drop is attributed to the planned phase-out of third-party product sales, which already fell by 42.3% to €19.2 million in 2025. Organic growth from Valneva's own branded products has not yet fully compensated for this reduction. When the final numbers are published, investors will scrutinize the details surrounding margin progression and liquidity runway.

Pipeline Focus: VLA15 Holds Transformational Potential

The far more substantial driver for the company's valuation is its Lyme disease vaccine candidate, VLA15, developed in partnership with Pfizer. The Phase 3 VALOR trial, involving approximately 9,500 participants, is ongoing. Final data readouts are anticipated in the first half of 2026. VLA15 is the only Lyme borreliosis vaccine program globally in late-stage clinical development and carries FDA Fast Track designation.

Should the trial yield positive results, Pfizer plans to submit regulatory applications to both the FDA and EMA before the end of 2026. For Valneva, this would trigger an initial $143 million in milestone payments, followed by tiered royalties on sales between 14% and 22%, plus an additional $100 million in cumulative sales-based milestones.

Secondary Asset and Technical Positioning

Valneva's pipeline features a second key asset: a Shigella vaccine candidate. Data for this program is expected in the second half of 2026. The World Health Organization has prioritized Shigella vaccine development, and no approved multivalent vaccine currently exists.

From a technical analysis perspective, the share price has advanced roughly 19% since the start of the year, trading notably above its key moving averages. The Relative Strength Index (RSI) reading of 15.5 indicates a deeply oversold condition, which could suggest a potential for a technical rebound—provided the fundamental news flow in the coming weeks contains no negative surprises. The imminent Phase 3 data for VLA15 represents the next critical inflection point for the company.